```html

Zollinger‑Ellison‑Like Gastritis: A Comprehensive Medical Guide

Overview

Zollinger‑Ellison‑like gastritis (ZELG) is a form of chronic gastritis that mimics the high‑acid environment seen in Zollinger‑Ellison syndrome (ZES) but occurs without a gastrin‑producing neuroendocrine tumor. Instead, the stomach lining is inflamed and secretes excessive gastric acid due to functional hypergastrinemia, H. pylori infection, or other non‑neoplastic triggers. The condition can lead to peptic ulcer disease, gastro‑esophageal reflux, and, in severe cases, gastric bleeding.

Who it affects: Adults aged 30–70 are most commonly diagnosed, with a slight male predominance (≈55 %). While rare in children, sporadic cases are reported, especially when H. pylori infection is present.

Prevalence: Precise epidemiologic data are limited because ZELG is often grouped under “hyperacidic gastritis.” Estimates suggest that 5–10 % of patients with chronic gastritis exhibit acid hypersecretion comparable to ZES (NIH, 2020).

Symptoms

Symptoms vary from mild dyspepsia to severe ulcer‑related pain. Common manifestations include:

• Upper abdominal (epigastric) pain: Burning or gnawing pain that may improve with meals (duodenal ulcer pattern) or worsen after eating (gastric ulcer pattern).
• Heartburn and acid reflux: A sour taste, regurgitation, or a burning sensation behind the breastbone.
• Nausea & vomiting: May be occasional or persistent; vomiting of blood (hematemesis) indicates ulcer bleeding.
• Loss of appetite & early satiety: Due to gastric distension or ulcer pain.
• Weight loss: Often secondary to reduced intake or malabsorption.
• Gastrointestinal bleeding: Melena (black, tarry stools) or hematochezia (bright red blood) signals ulcer erosion.
• Diarrhea or steatorrhea: Excess acid can inactivate pancreatic enzymes, leading to maldigestion.
• Fatigue & anemia: Chronic blood loss can cause iron‑deficiency anemia.
• Rare neurologic signs: Severe hypergastrinemia may cause gastrinomas‑like symptoms (e.g., flushing), but these are uncommon in ZELG.

Causes and Risk Factors

Unlike classic ZES, ZELG does not involve a gastrin‑producing tumor. The main contributors are:

1. Helicobacter pylori infection: The bacterium stimulates G‑cells to release gastrin, leading to acid overproduction.<sup>1</sup>
2. Chronic use of proton‑pump inhibitor (PPI) rebound: Abrupt discontinuation can cause hypergastrinemia and transient acid surge.
3. Genetic predisposition: Polymorphisms in the CYP2C19 gene affect PPI metabolism and may predispose to acid hypersecretion.
4. Autoimmune gastritis: Parietal‑cell loss reduces acid, but compensatory hypergastrinemia may paradoxically increase acid output in residual cells.
5. Excessive alcohol or tobacco use: Both irritate the gastric mucosa and increase gastrin release.
6. Dietary factors: High‑protein, high‑spice meals can stimulate gastrin secretion.

Risk factors include prior H. pylori infection, long‑term PPI therapy, smoking, heavy alcohol consumption, and a family history of endocrine tumors (MEN‑1 syndrome), even though MEN‑1 is more often linked to true ZES.

Diagnosis

Diagnosing ZELG requires a systematic approach to exclude a gastrinoma and confirm hyperacidic gastritis.

1. Clinical evaluation

• Detailed history (symptom pattern, medication use, prior infections).
• Physical exam focusing on epigastric tenderness and signs of anemia.

2. Laboratory tests

• Serum gastrin level: Typically 2–5× upper normal limit in ZELG (vs. >10× in ZES). Fasting draw is essential.
• Secretin stimulation test: Helps differentiate ZES (gastrin rises >120 pg/mL) from ZELG (minimal or no rise).
• Complete blood count (CBC) for anemia, and iron studies if bleeding is suspected.
• Helicobacter pylori testing (urea breath test, stool antigen, or biopsy).

3. Endoscopic assessment

• Upper endoscopy (EGD): Visualizes erosions, ulcers, and allows biopsy for H. pylori, intestinal metaplasia, or neoplasia.
• Biopsy specimens are stained with Gomori trichrome and immunohistochemistry for gastrin‑producing cells.

4. Imaging

• CT or MRI of the abdomen: Performed when gastrin levels are markedly elevated to rule out gastrinomas.
• Somatostatin receptor scintigraphy (OctreoScan): Highly sensitive for neuroendocrine tumors; a negative scan supports ZELG.

5. Additional tests

• 24‑hour gastric pH monitoring (ambulatory or intragastric) can document persistent hyperacidity (pH <2 for >70 % of the time).

Treatment Options

Therapy aims to suppress acid, eradicate H. pylori, heal ulcers, and prevent recurrence.

1. Pharmacologic therapy

• Proton‑pump inhibitors (PPIs): Omeprazole 20–40 mg BID or esomeprazole 20–40 mg BID are first‑line; they raise gastric pH and promote ulcer healing. For refractory cases, high‑dose PPIs (e.g., 80 mg daily) may be needed.
• H2‑receptor antagonists: Ranitidine or famotidine may be added for breakthrough symptoms, though PPIs are superior for acid control.
• Antibiotic eradication of H. pylori: Standard triple therapy (clarithromycin‑based) or quadruple therapy (bismuth‑based) for 10–14 days. Success rates >85 % when adherence is good (CDC, 2023).
• Prokinetics (e.g., domperidone): Helpful if delayed gastric emptying contributes to symptoms.
• Somatostatin analogs (e.g., octreotide): Rarely used; considered only if hypergastrinemia persists despite maximal PPI therapy and no tumor is found.

2. Endoscopic or surgical interventions

• Endoscopic hemostasis: Clips, thermal coagulation, or injection therapy for actively bleeding ulcers.
• Partial gastrectomy: Historically performed for refractory ZES; now reserved for complicated ZELG with uncontrollable ulcer disease, after thorough tumor exclusion.

3. Lifestyle and dietary modifications

• Avoid NSAIDs, aspirin, and other ulcerogenic drugs.
• Limit caffeine, alcohol, and very spicy foods that stimulate acid.
• Adopt a balanced diet rich in fruits, vegetables, and lean protein.
• Maintain a healthy weight; obesity can increase reflux and ulcer risk.

Living with Zollinger‑Ellison‑Like Gastritis

Chronic conditions require practical daily strategies:

• Medication adherence: Take PPIs 30 minutes before breakfast and dinner; never skip doses.
• Scheduled H. pylori testing: Repeat breath test 4–6 weeks after eradication therapy to confirm cure.
• Symptom diary: Record meals, pain episodes, and medication timing to identify triggers.
• Stress management: Mind‑body techniques (yoga, meditation) can lessen perceived pain.
• Regular follow‑up: Endoscopy every 1–2 years if ulcers persist, sooner if symptoms worsen.
• Vaccinations: If long‑term PPI use, consider hepatitis B and C screening and flu/vaccine updates, as altered gut flora may affect immunity.

Prevention

While ZELG cannot be entirely prevented, risk reduction is achievable:

• Screen and treat H. pylori infection early, especially in populations with >30 % prevalence (WHO, 2022).
• Use NSAIDs and aspirin with caution; co‑prescribe a PPI when chronic use is unavoidable.
• Quit smoking – risk of ulcer disease is 2–3 times higher in smokers.
• Limit alcohol to ≤2 drinks/day for men, ≤1 drink/day for women.
• Avoid abrupt discontinuation of PPIs; taper slowly under physician guidance.

Complications

If untreated, ZELG can lead to serious health problems:

• Peptic ulcer disease: Chronic ulcers may perforate (medical emergency).
• Upper gastrointestinal bleeding: May cause anemia or require transfusion.
• Gastric outlet obstruction: Scarring from repeated ulcers can block stomach emptying.
• Barrett’s esophagus: Persistent reflux may lead to metaplastic changes and increase esophageal adenocarcinoma risk.
• Gastric cancer: Long‑standing hyperacidic gastritis is a modest risk factor, especially with concurrent H. pylori infection.
• Nutritional deficiencies: Iron, vitamin B12, and calcium malabsorption due to acidic milieu.

When to Seek Emergency Care

---

References:
1. Mayo Clinic. “Helicobacter pylori infection.” 2023.
2. National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison syndrome.” 2022.
3. CDC. “Helicobacter pylori.” 2023.
4. WHO. “Helicobacter pylori.” Fact sheet, 2022.
5. Cleveland Clinic. “Peptic ulcer disease.” 2024.
6. NIH. “Gastric acid hypersecretion.” 2020.

```